Cidara Therapeutics Stock Buy Hold or Sell Recommendation
| CDTX Stock | USD 22.05 0.31 1.39% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cidara Therapeutics is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Cidara Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Cidara Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Cidara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide. In addition, we conduct extensive research on individual companies such as Cidara and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Cidara |
Execute Cidara Therapeutics Buy or Sell Advice
The Cidara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cidara Therapeutics. Macroaxis does not own or have any residual interests in Cidara Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cidara Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cidara Therapeutics Trading Alerts and Improvement Suggestions
| Cidara Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (169.83 M) with loss before overhead, payroll, taxes, and interest of (70.6 M). | |
| Cidara Therapeutics currently holds about 53.08 M in cash with (176.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Cidara Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Analysts Issue Forecasts for CDTX FY2029 Earnings |
Cidara Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cidara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cidara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Cidara Therapeutics Returns Distribution Density
The distribution of Cidara Therapeutics' historical returns is an attempt to chart the uncertainty of Cidara Therapeutics' future price movements. The chart of the probability distribution of Cidara Therapeutics daily returns describes the distribution of returns around its average expected value. We use Cidara Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cidara Therapeutics returns is essential to provide solid investment advice for Cidara Therapeutics.
| Mean Return | -0.0028 | Value At Risk | -7.85 | Potential Upside | 6.73 | Standard Deviation | 4.65 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cidara Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cidara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Cidara Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Cidara Therapeutics back and forth among themselves.
| Shares | Blackrock Inc | 2024-12-31 | 55.5 K | Longwood Capital Partners Llc | 2024-12-31 | 54.5 K | Ikarian Capital, Llc | 2024-12-31 | 53.9 K | Geode Capital Management, Llc | 2024-12-31 | 53.1 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 49.6 K | Stempoint Capital Lp | 2024-12-31 | 47.6 K | Ubs Group Ag | 2024-12-31 | 46.9 K | Susquehanna International Group, Llp | 2024-12-31 | 42.6 K | Millennium Management Llc | 2024-12-31 | 36 K | Bvf Inc | 2024-12-31 | 1.1 M | Ra Capital Management, Llc | 2024-12-31 | 1.1 M |
Cidara Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (17.3M) | 19.3M | (29.5M) | 3.0M | 160.4M | 168.4M | |
| Free Cash Flow | (54.6M) | (25.3M) | (28.6M) | (22.9M) | (176.7M) | (167.8M) | |
| Other Non Cash Items | 21K | 15K | 1K | 1.2M | 3.1M | 3.2M | |
| Capital Expenditures | 186K | 41K | 118K | 505K | 129K | 122.6K | |
| Net Income | (72.1M) | (42.5M) | (29.8M) | (22.9M) | (169.8M) | (161.3M) | |
| End Period Cash Flow | 42.9M | 62.3M | 32.7M | 35.8M | 196.2M | 206.0M | |
| Investments | (186K) | (41K) | (118K) | (505K) | (129K) | (135.5K) | |
| Depreciation | 229K | (1.2M) | 1.2M | 118K | 233K | 255.4K | |
| Change To Netincome | 4.7M | 4.1M | 2.6M | 3.5M | 4.1M | 3.9M |
Cidara Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cidara Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cidara Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cidara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 4.72 | |
Ir | Information ratio | 0.02 |
Cidara Therapeutics Volatility Alert
Cidara Therapeutics exhibits very low volatility with skewness of -0.47 and kurtosis of 0.61. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cidara Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cidara Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cidara Therapeutics Fundamentals Vs Peers
Comparing Cidara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cidara Therapeutics' direct or indirect competition across all of the common fundamentals between Cidara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cidara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cidara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cidara Therapeutics to competition |
| Fundamentals | Cidara Therapeutics | Peer Average |
| Return On Equity | -2.2 | -0.31 |
| Return On Asset | -0.4 | -0.14 |
| Operating Margin | (71.54) % | (5.51) % |
| Current Valuation | 55.28 M | 16.62 B |
| Shares Outstanding | 10.95 M | 571.82 M |
| Shares Owned By Insiders | 1.37 % | 10.09 % |
| Shares Owned By Institutions | 69.43 % | 39.21 % |
| Number Of Shares Shorted | 181.99 K | 4.71 M |
| Price To Earning | (2.21) X | 28.72 X |
| Price To Book | 1.48 X | 9.51 X |
| Price To Sales | 189.43 X | 11.42 X |
| Revenue | 1.27 M | 9.43 B |
| Gross Profit | (70.6 M) | 27.38 B |
| EBITDA | (176.1 M) | 3.9 B |
| Net Income | (169.83 M) | 570.98 M |
| Cash And Equivalents | 53.08 M | 2.7 B |
| Cash Per Share | 0.74 X | 5.01 X |
| Total Debt | 3.58 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 1.93 X | 2.16 X |
| Book Value Per Share | 14.92 X | 1.93 K |
| Cash Flow From Operations | (176.53 M) | 971.22 M |
| Short Ratio | 2.38 X | 4.00 X |
| Earnings Per Share | (26.82) X | 3.12 X |
| Target Price | 36.6 | |
| Number Of Employees | 38 | 18.84 K |
| Beta | 0.88 | -0.15 |
| Market Capitalization | 241.52 M | 19.03 B |
| Total Asset | 214.8 M | 29.47 B |
| Retained Earnings | (611.26 M) | 9.33 B |
| Working Capital | 161.18 M | 1.48 B |
| Current Asset | 108.22 M | 9.34 B |
| Current Liabilities | 5.97 M | 7.9 B |
Note: Insider Trading [view details]
Cidara Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cidara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cidara Therapeutics Buy or Sell Advice
When is the right time to buy or sell Cidara Therapeutics? Buying financial instruments such as Cidara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cidara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.